Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Syndax Pharmaceuticals Inc SNDX

Healthcare Biotechnology
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute... see more

Recent & Breaking News (NDAQ:SNDX)

Syndax Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Clinical and Business Update

PR Newswire August 6, 2020

Syndax Announces Participation in BTIG Virtual Biotechnology Conference

PR Newswire August 3, 2020

Syndax to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020

PR Newswire July 30, 2020

Syndax Pharmaceuticals Appoints Daphne Karydas as Chief Financial Officer

PR Newswire July 7, 2020

ECOG-ACRIN Provides Syndax Pharmaceuticals With Results of Phase 3 E2112 Trial of Entinostat Plus Exemestane in Patients with HR+, HER2- Breast Cancer

PR Newswire May 21, 2020

Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire May 12, 2020

Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update

PR Newswire May 7, 2020

Syndax Announces Pricing of Public Offering of Common Stock

PR Newswire April 30, 2020

Syndax Announces Proposed Public Offering of Common Stock

PR Newswire April 29, 2020

Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias

PR Newswire April 27, 2020

Syndax Pharmaceuticals Announces Three Presentations at the 2020 American Association for Cancer Research Virtual Annual Meeting

PR Newswire April 14, 2020

Syndax Pharmaceuticals Reports Fourth Quarter 2019 Financial Results and Provides Clinical and Business Update

PR Newswire March 3, 2020

Syndax to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 3, 2020

PR Newswire February 25, 2020

Syndax Announces Participation at Two Upcoming Investor Conferences

PR Newswire February 18, 2020

Syndax Announces $35.0 Million Offering of Common Stock and Enters Term Sheet for Loan with Hercules Capital for up to $30 Million

PR Newswire January 31, 2020

Science Magazine Publishes Results from Preclinical Study on the Activity of Menin-MLL Inhibition for the Treatment of NPM1 Acute Myeloid Leukemia

PR Newswire January 30, 2020

Syndax Pharmaceuticals Highlights 2020 Clinical and Corporate Outlook

PR Newswire January 10, 2020

Syndax Pharmaceuticals Announces Plans to Commence Phase 2 Expansion Cohort of SNDX-6352 for the Treatment of Chronic Graft Versus Host Disease

PR Newswire December 10, 2019

Syndax Announces Preclinical Results Supporting Development of its Portfolio of Menin Inhibitors In Mixed Lineage Leukemias

PR Newswire December 9, 2019

Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update

PR Newswire November 7, 2019